Francine BÃ©har-Cohen

List of Publications by Year
in descending order

132	5,826	81839	91828
papers	citations	39 h-index	69 g-index

144	144	144	5074
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Central serous chorioretinopathy imaging biomarkers. British Journal of Ophthalmology, 2022, 106, 553-558.	2.1	23
2	Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. Progress in Retinal and Eye Research, 2022, 86, 100973.	7.3	133
3	Type one macular neovascularization in central serous chorioretinopathy: Short-term response to anti-vascular endothelial growth factor therapy. Eye, 2022, 36, 1945-1950.	1.1	4
4	Validation of central serous chorioretinopathy multimodal imaging-based classification system. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 1161-1169.	1.0	15
5	Chronic Systemic Dexamethasone Regulates the Mineralocorticoid/Glucocorticoid Pathways Balance in Rat Ocular Tissues. International Journal of Molecular Sciences, 2022, 23, 1278.	1.8	8
6	Mineralocorticoid pathway in retinal health and diseases. British Journal of Pharmacology, 2022, 179, 3190-3204.	2.7	8
7	Fluocinolone acetonide implant in diabetic macular edema: International expertsâ€™ panel consensus guidelines and treatment algorithm. European Journal of Ophthalmology, 2022, 32, 1890-1899.	0.7	17
8	Comparative Analysis of Urso- and Tauroursodeoxycholic Acid Neuroprotective Effects on Retinal Degeneration Models. Pharmaceuticals, 2022, 15, 334.	1.7	3
9	Clinical Characteristics and Multimodal Imaging Findings of Central Serous Chorioretinopathy in Women versus Men. Journal of Clinical Medicine, 2022, 11, 1706.	1.0	4
10	OCT Angiography Fractal Analysis of Choroidal Neovessels Secondary to Central Serous Chorioretinopathy, in a Caucasian Cohort. Journal of Clinical Medicine, 2022, 11, 1443.	1.0	6
11	Current and Future Treatments for Diabetic Retinopathy. Pharmaceutics, 2022, 14, 812.	2.0	3
12	Ocular Barriers and Their Influence on Gene Therapy Products Delivery. Pharmaceutics, 2022, 14, 998.	2.0	13
13	The Use of Polymer Blends in the Treatment of Ocular Diseases. Pharmaceutics, 2022, 14, 1431.	2.0	9
14	Choroidal imaging in patients with Cushing syndrome. Acta Ophthalmologica, 2021, 99, 533-537.	0.6	8
15	The antidiabetic drug glibenclamide exerts direct retinal neuroprotection. Translational Research, 2021, 229, 83-99.	2.2	18
16	Pachychoroid: current concepts on clinical features and pathogenesis. Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259, 1385-1400.	1.0	40
17	Oral Ursodeoxycholic Acid Crosses the Blood Retinal Barrier in Patients with Retinal Detachment and Protects Against Retinal Degeneration in an Ex Vivo Model. Neurotherapeutics, 2021, 18, 1325-1338.	2.1	13
18	Effect of eplerenone on choroidal blood flow changes during isometric exercise in patients with chronic central serous chorioretinopathy. Acta Ophthalmologica, 2021, 99, e1375-e1381.	0.6	3

#	Article	IF	Citations
19	Evaluation of an Intravitreal Rho-Associated Kinase Inhibitor Depot Formulation in a Rat Model of Diabetic Retinopathy. Pharmaceutics, 2021, 13, 1105.	2.0	3
20	Meteorin Is a Novel Therapeutic Target for Wet Age-Related Macular Degeneration. Journal of Clinical Medicine, 2021, 10, 2973.	1.0	5
21	Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model. Pharmaceutics, 2021, 13, 1095.	2.0	12
22	Mineralocorticoid Receptor Pathway and Its Antagonism in a Model of Diabetic Retinopathy. Diabetes, 2021, 70, 2668-2682.	0.3	14
23	Pathogenic Effects of Mineralocorticoid Pathway Activation in Retinal Pigment Epithelium. International Journal of Molecular Sciences, 2021, 22, 9618.	1.8	11
24	Mid-Phase Hyperfluorescent Plaques Seen on Indocyanine Green Angiography in Patients with Central Serous Chorioretinopathy. Journal of Clinical Medicine, 2021, 10, 4525.	1.0	11
25	COVID-19 Associated Choroidopathy. Journal of Clinical Medicine, 2021, 10, 4686.	1.0	9
26	Wnt6 plays a complex role in maintaining human limbal stem/progenitor cells. Scientific Reports, 2021, 11, 20948.	1.6	6
27	Central Serous Chorioretinopathy. Retina, 2021, Publish Ahead of Print, .	1.0	0
28	Did the COVID-19 Pandemic Increase the Incidence of Acute Macular Neuroretinopathy?. Journal of Clinical Medicine, 2021, 10, 5038.	1.0	32
29	Letter to the Editor From Behar-Cohen et al.: â€œThe Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathyâ€• Journal of Clinical Endocrinology and Metabolism, 2021, , .	1.8	1
30	CHANGES IN VISUAL ACUITY AND PHOTORECEPTOR DENSITY USING ADAPTIVE OPTICS AFTER RETINAL DETACHMENT REPAIR. Retina, 2020, 40, 376-386.	1.0	14
31	Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy. British Journal of Ophthalmology, 2020, 104, 910-916.	2.1	18
32	Cutaneous Wound Healing in Diabetic Mice Is Improved by Topical Mineralocorticoid Receptor Blockade. Journal of Investigative Dermatology, 2020, 140, 223-234.e7.	0.3	40
33	Ocular Biodistribution of Spironolactone after a Single Intravitreal Injection of a Biodegradable Sustained-Release Polymer in Rats. Molecular Pharmaceutics, 2020, 17, 59-69.	2.3	2
34	An in vitro Model of Human Retinal Detachment Reveals Successive Death Pathway Activations. Frontiers in Neuroscience, 2020, 14, 571293.	1.4	6
35	Multimodal Imaging-Based Central Serous Chorioretinopathy Classification. Ophthalmology Retina, 2020, 4, 1043-1046.	1.2	64
36	Transferrin Non-Viral Gene Therapy for Treatment of Retinal Degeneration. Pharmaceutics, 2020, 12, 836.	2.0	11

#	Article	IF	Citations
37	From Rust to Quantum Biology: The Role of Iron in Retina Physiopathology. Cells, 2020, 9, 705.	1.8	32
38	Transscleral optical phase imaging of the human retina. Nature Photonics, 2020, 14, 439-445.	15.6	25
39	Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2020, 395, 294-303.	6.3	134
40	Angiotensin II and aldosterone: Co-conspirators in ocular physiology and disease. Experimental Eye Research, 2020, 194, 108005.	1.2	7
41	Glial cells of the human fovea. Molecular Vision, 2020, 26, 235-245.	1.1	10
42	Antidepressant medication and ocular factors in association with the need for anti-VEGF retreatment in neovascular age-related macular degeneration. British Journal of Ophthalmology, 2019, 103, 811-815.	2.1	0
43	Discrepancy in current central serous chorioretinopathyÂclassification. British Journal of Ophthalmology, 2019, 103, 737-742.	2.1	45
44	Effect of acute and chronic aldosterone exposure on the retinal pigment epithelium-choroid complex in rodents. Experimental Eye Research, 2019, 187, 107747.	1.2	25
45	Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence. Experimental Eye Research, 2019, 187, 107754.	1.2	25
46	Iron is neurotoxic in retinal detachment and transferrin confers neuroprotection. Science Advances, 2019, 5, eaau9940.	4.7	48
47	Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration. Nature Communications, 2019, 10, 369.	5.8	47
48	Recent advances in slow and sustained drug release for retina drug delivery. Expert Opinion on Drug Delivery, 2019, 16, 679-686.	2.4	15
49	Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives. Drug Discovery Today, 2019, 24, 1685-1693.	3.2	78
50	Potential antiedematous effects of intravitreous anti-VEGF, unrelated to VEGF neutralization. Drug Discovery Today, 2019, 24, 1436-1439.	3.2	4
51	Ocular biocompatibility of dexamethasone acetate loaded poly(Ɛ-caprolactone) nanofibers. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 20-30.	2.0	36
52	Pathophysiology of CSCR. , 2019, , 3-10.		0
53	PATTERNS OF CHORIOCAPILLARIS FLOW SIGNAL VOIDS IN CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2019, 39, 2178-2188.	1.0	40
54	Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy. British Journal of Ophthalmology, 2019, 103, 1184-1189.	2.1	26

#	Article	IF	Citations
55	Review: The bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease. Molecular Vision, 2019, 25, 610-624.	1.1	33
56	Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases. Acta Ophthalmologica, 2018, 96, e1-e9.	0.6	60
57	RISK FACTORS FOR RECURRENCES OF CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2018, 38, 1403-1414.	1.0	59
58	CONCURRENT IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 AND CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2018, 38, S67-S78.	1.0	15
59	Mechanisms of macular edema: Beyond the surface. Progress in Retinal and Eye Research, 2018, 63, 20-68.	7.3	422
60	Proteome and Metabolome of Subretinal Fluid in Central Serous Chorioretinopathy and Rhegmatogenous Retinal Detachment: A Pilot Case Study. Translational Vision Science and Technology, 2018, 7, 3.	1.1	34
61	Towards an Optimized Use of Ocular Corticosteroids: EURETINA Award Lecture 2017. Ophthalmologica, 2018, 240, 111-119.	1.0	8
62	Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: Preclinical evaluation of the medicinal product. Journal of Controlled Release, 2018, 285, 244-251.	4.8	24
63	Management of central serous chorioretinopathy: Expert panel discussion. Indian Journal of Ophthalmology, 2018, 66, 1700.	0.5	7
64	Ocular safety of Intravitreal Clindamycin Hydrochloride Released by PLGA Implants. Pharmaceutical Research, 2017, 34, 1083-1092.	1.7	10
65	Cone Genesis Tracing by the Chrnb4-EGFP Mouse Line: Evidences of Cellular Material Fusion after Cone Precursor Transplantation. Molecular Therapy, 2017, 25, 634-653.	3.7	56
66	VOLUME-RENDERED ANGIOGRAPHIC AND STRUCTURAL OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF MACULAR TELANGIECTASIA TYPE 2. Retina, 2017, 37, 424-435.	1.0	50
67	EFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE. Retina, 2017, 37, 2226-2237.	1.0	13
68	ACUTE CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2017, 37, 1905-1915.	1.0	102
69	Central Serous Chorioretinopathy. Developments in Ophthalmology, 2017, 58, 27-38.	0.1	25
70	The Academicâ€“Industrial Complexity: Failure to Launch. Trends in Pharmacological Sciences, 2017, 38, 1052-1060.	4.0	10
71	Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site. Journal of Controlled Release, 2017, 266, 187-197.	4.8	29
72	ROCK-1 mediates diabetes-induced retinal pigment epithelial and endothelial cell blebbing: Contribution to diabetic retinopathy. Scientific Reports, 2017, 7, 8834.	1.6	36

#	Article	IF	Citations
73	Evaluation of tolerance to lentiviral LV-RPE65 gene therapy vector after subretinal delivery in non-human primates. Translational Research, 2017, 188, 40-57.e4.	2.2	21
74	Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. International Ophthalmology, 2017, 37, 1115-1125.	0.6	46
75	Mechanisms of Macular Edema. , 2017, , 7-25.		0
76	Irvine-Gass Macular Edema Responding to the Combination of Oral Mineralocorticoid-Receptor Antagonist With Dexamethasone Drops. Ophthalmic Surgery Lasers and Imaging Retina, 2017, 48, 936-942.	0.4	4
77	Bioactive Glass Nanoparticles-Loaded Poly(É›-caprolactone) Nanofiber as Substrate for ARPE-19 Cells. Journal of Nanomaterials, 2016, 2016, 1-12.	1.5	11
78	Oral Mineralocorticoid-Receptor Antagonists: Real-Life Experience in Clinical Subtypes of Nonresolving Central Serous Chorioretinopathy With Chronic Epitheliopathy. Translational Vision Science and Technology, 2016, 5, 2.	1.1	89
79	Corticosteroids and the retina. Current Opinion in Neurology, 2016, 29, 49-54.	1.8	29
80	Shift Work: A Risk Factor for Central Serous Chorioretinopathy. American Journal of Ophthalmology, 2016, 165, 23-28.	1.7	52
81	Macular Telangiectasia Type 1: Capillary Density and Microvascular Abnormalities Assessed by Optical Coherence Tomography Angiography. American Journal of Ophthalmology, 2016, 167, 18-30.	1.7	32
82	Light-induced retinal damage using different light sources, protocols and rat strains reveals LED phototoxicity. Neuroscience, 2016, 339, 296-307.	1.1	119
83	Bloodâ€“brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of Pâ€glycoprotein on a novel verapamil influx carrier. British Journal of Pharmacology, 2016, 173, 497-510.	2.7	50
84	Treatment of Uveitis by In Situ Administration of Ex Vivoâ€“Activated Polyclonal Regulatory T Cells. Journal of Immunology, 2016, 196, 2109-2118.	0.4	25
85	Retinal safety of intravitreal rtPA in healthy rats and under excitotoxic conditions. Molecular Vision, 2016, 22, 1332-1341.	1.1	3
86	SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2015, 35, 2505-2515.	1.0	116
87	Targeting iron-mediated retinal degeneration by local delivery of transferrin. Free Radical Biology and Medicine, 2015, 89, 1105-1121.	1.3	30
88	Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Progress in Retinal and Eye Research, 2015, 48, 82-118.	7.3	712
89	High Prevalence of PRPH2 in Autosomal Dominant Retinitis Pigmentosa in France and Characterization of Biochemical and Clinical Features. American Journal of Ophthalmology, 2015, 159, 302-314.	1.7	29
90	Glucocorticoids Exert Direct Toxicity on Microvasculature: Analysis of Cell Death Mechanisms. Toxicological Sciences, 2015, 143, 441-453.	1.4	36

#	Article	IF	Citations
91	Choroidal Mast Cells in Retinal Pathology. American Journal of Pathology, 2015, 185, 2083-2095.	1.9	24
92	In vitro and in vivo ocular biocompatibility of electrospun poly(É›-caprolactone) nanofibers. European Journal of Pharmaceutical Sciences, 2015, 73, 9-19.	1.9	48
93	En Face Optical Coherence Tomography of Foveal Microstructure in Full-Thickness Macular Hole: A Model to Study Perifoveal MÃ¼ller Cells. American Journal of Ophthalmology, 2015, 159, 1142-1151.e3.	1.7	52
94	On the use of an appropriate TdT-mediated dUTPâ€“biotin nick end labeling assay to identify apoptotic cells. Analytical Biochemistry, 2015, 480, 37-41.	1.1	15
95	Sustained-Release Steroids for the Treatment of Diabetic Macular Edema. Current Diabetes Reports, 2015, 15, 99.	1.7	16
96	A New CRB1 Rat Mutation Links MÃ¼ller Glial Cells to Retinal Telangiectasia. Journal of Neuroscience, 2015, 35, 6093-6106.	1.7	54
97	Ultraviolet damage to the eye revisited: eye-sun protection factor (E-SPF®), a new ultraviolet protection label for eyewear. Clinical Ophthalmology, 2014, 8, 87.	0.9	73
98	Resolution of foveal detachment in dome-shaped macula after treatment by spironolactone: report of two cases and mini-review of the literature. Clinical Ophthalmology, 2014, 8, 999.	0.9	32
99	Reply. Retina, 2014, 34, e20-e21.	1.0	0
100	Method for Retinal Gene Repair in Neonatal Mouse. Methods in Molecular Biology, 2014, 1114, 387-398.	0.4	1
101	MINERALOCORTICOID RECEPTOR ANTAGONISM IN THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Retina, 2013, 33, 2096-2102.	1.0	188
102	PKCÎ¶ Mediates Breakdown of Outer Blood-Retinal Barriers in Diabetic Retinopathy. PLoS ONE, 2013, 8, e81600.	1.1	46
103	Ocular Distribution, Spectrum of Activity, and In Vivo Viral Neutralization of a Fully Humanized Anti-Herpes Simplex Virus IgG Fab Fragment following Topical Application. Antimicrobial Agents and Chemotherapy, 2012, 56, 1390-1402.	1.4	16
104	Suprachoroidal Electrotransfer: A Nonviral Gene Delivery Method to Transfect the Choroid and the Retina Without Detaching the Retina. Molecular Therapy, 2012, 20, 1559-1570.	3.7	50
105	Drug delivery to the eye: current trends and future perspectives. Therapeutic Delivery, 2012, 3, 1135-1137.	1.2	7
106	Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. Journal of Clinical Investigation, 2012, 122, 2672-2679.	3.9	316
107	The Aldosterone-Mineralocorticoid Receptor Pathway Exerts Anti-Inflammatory Effects in Endotoxin-Induced Uveitis. PLoS ONE, 2012, 7, e49036.	1.1	30
108	Placental Growth Factor Contributes to Micro-Vascular Abnormalization and Blood-Retinal Barrier Breakdown in Diabetic Retinopathy. PLoS ONE, 2011, 6, e17462.	1.1	65

#	Article	IF	Citations
109	On the retinal toxicity of intraocular glucocorticoids. Biochemical Pharmacology, 2010, 80, 1878-1886.	2.0	38
110	The ciliary smooth muscle electrotransfer: basic principles and potential for sustained intraocular production of therapeutic proteins. Journal of Gene Medicine, 2010, 12, 904-919.	1.4	20
111	The outer limiting membrane (OLM) revisited: clinical implications. Clinical Ophthalmology, 2010, 4, 183.	0.9	132
112	The neuroretina is a novel mineralocorticoid target: aldosterone upâ€regulates ion and water channels in MÃ¼ller glial cells. FASEB Journal, 2010, 24, 3405-3415.	0.2	129
113	Overexpressed or intraperitoneally injected human transferrin prevents photoreceptor degeneration in rd10 mice. Molecular Vision, 2010, 16, 2612-25.	1.1	23
114	Local Ocular Immunomodulation Resulting from Electrotransfer of Plasmid Encoding Soluble TNF Receptors in the Ciliary Muscle. , 2009, 50, 1761.		23
115	Poly-Îµ-Caprolactone Intravitreous Devices: An In Vivo Study. , 2009, 50, 2312.		43
116	Pharmacokinetics and Posterior Segment Biodistribution of ESBA105, an Antiâ€“TNF-Î± Single-Chain Antibody, upon Topical Administration to the Rabbit Eye. , 2009, 50, 771.		58
117	Effects of triamcinolone acetonide on vessels of the posterior segment of the eye. Molecular Vision, 2009, 15, 2634-48.	1.1	23
118	Dexamethasone-loaded poly(Îµ-caprolactone) intravitreal implants: A pilot study. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 637-646.	2.0	76
119	The protective role of transferrin in MÃ¼ller glial cells after iron-induced toxicity. Molecular Vision, 2008, 14, 928-41.	1.1	20
120	Electrically Assisted Ocular Gene Therapy. Survey of Ophthalmology, 2007, 52, 196-208.	1.7	55
121	Single-stranded oligonucleotide-mediated in vivo gene repair in the rd1 retina. Molecular Vision, 2007, 13, 692-706.	1.1	24
122	Glucocorticoids induce retinal toxicity through mechanisms mainly associated with paraptosis. Molecular Vision, 2007, 13, 1746-57.	1.1	43
123	Early Effects of Intravitreal Triamcinolone on Macular Edema. Ophthalmology, 2006, 113, 2048-2053.	2.5	28
124	Oligonucleotide-Polyethylenimine Complexes Targeting Retinal Cells: Structural Analysis and Application to Anti-TGFÎ²-2 Therapy. Pharmaceutical Research, 2006, 23, 770-781.	1.7	48
125	Sustained release of nanosized complexes of polyethylenimine and anti-TGF-Î²2 oligonucleotide improves the outcome of glaucoma surgery. Journal of Controlled Release, 2006, 112, 369-381.	4.8	93
126	Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNFâ€Î± soluble receptor in uveitis. FASEB Journal, 2006, 20, 389-391.	0.2	59

#	Article	IF	Citations
127	Enhanced oligonucleotide delivery to mouse retinal cells using iontophoresis. Molecular Vision, 2006, 12, 1098-107.	1.1	20
128	Ocular gene therapy: a review of nonviral strategies. Molecular Vision, 2006, 12, 1334-47.	1.1	55
129	Downregulation of IRS-1 Expression Causes Inhibition of Corneal Angiogenesis. , 2005, 46, 4072.		47
130	VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo. Molecular Vision, 2005, 11, 184-91.	1.1	33
131	Ocular biocompatibility of a poly(ortho ester) characterized by autocatalyzed degradation. Journal of Biomedical Materials Research Part B, 2003, 67A, 44-53.	3.0	27
132	Evaluation of a novel biomaterial in the suprachoroidal space of the rabbit eye. Investigative Ophthalmology and Visual Science, 2002, 43, 1533-9.	3.3	75